TRANSCODE THERAPEUTICS
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.
TRANSCODE THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.transcodetherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
28.05 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Google Tag Manager Google Analytics LetsEncrypt SSL By Default Global Site Tag IPv6 ReCAPTCHA
Similar Organizations
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Nymox Pharmaceutical
Nymox Pharmaceutical is a biopharmaceutical company.
Current Employees Featured
Philippe P. Calais Director @ Transcode Therapeutics
Director
2018-11-01
Tom Fitzgerald Chief Financial Officer @ Transcode Therapeutics
Chief Financial Officer
Zdravka Medarova Chief Technology Officer @ Transcode Therapeutics
Chief Technology Officer
2021-10-01
Founder
Stock Details
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Transcode Therapeutics
TRITON FUNDS LLC
TRITON FUNDS LLC investment in Post-IPO Equity - Transcode Therapeutics
National Cancer Institute
National Cancer Institute investment in Grant - Transcode Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - Transcode Therapeutics
Red Cedar Ventures
Red Cedar Ventures investment in Post-IPO Equity - Transcode Therapeutics
Red Cedar Ventures
Red Cedar Ventures investment in Seed Round - Transcode Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2024-03-28 | TransCode Therapeutics appoints Vlock as chief medical officer |
| 2024-01-12 | TransCode Therapeutics announces retirement of CEO |
| 2021-09-30 | TransCode Therapeutics Appoints Zdravka Medarova, Ph.D., as Chief Technology Officer |
Official Site Inspections
http://www.transcodetherapeutics.com Semrush global rank: 5.67 M Semrush visits lastest month: 1.25 K
- Host name: pages-custom-29.weebly.com
- IP address: 199.34.228.77
- Location: San Francisco United States
- Latitude: 37.7642
- Longitude: -122.3993
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94107
More informations about "Transcode Therapeutics"
About - TRANSCODE THERAPEUTICS, INC.
TransCode Therapeutics is a Boston-based biotechnology company focused on oncology. TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief …See details»
Investors Overview - TRANSCODE THERAPEUTICS, INC.
3 days ago TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA …See details»
Transcode Therapeutics - Crunchbase Company Profile …
Contact Email info@transcodetherapeutics.com TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the …See details»
TransCode Therapeutics, Inc. | LinkedIn
May 29, 2024 At the Ascent conference by the Alliance for mRNA Medicines, Zdravka Medarova, Ph.D., Chief Scientific Officer from TransCode Therapeutics, Inc., shared key lessons from the oligonucleotide sector ...See details»
Investor Relations - TransCode Therapeutics
Nov 9, 2022 The Investor Relations website contains information about TransCode Therapeutics's business for stockholders, potential investors, and financial analysts.See details»
Focus - TRANSCODE THERAPEUTICS, INC.
Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16(4):201-218.Liang X, et al. Biomed Pharmacother.2020;125:109997.; Damase TR, et al. Frontiers in Bioengineering ...See details»
TransCode Therapeutics - Overview, News & Similar companies
TransCode Therapeutics contact info: Phone number: (857) 837-3099 Website: www.transcodetherapeutics.com What does TransCode Therapeutics do? TransCode …See details»
TransCode Therapeutics, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TransCode Therapeutics, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
TransCode Therapeutics, Inc. Company Overview, Contact Details ...
Nov 27, 2024 John.Doe@transcodetherapeutics.com: 48%. See more formats. Frequently Asked Questions Where is TransCode Therapeutics, Inc. 's headquarters located? TransCode …See details»
TransCode Therapeutics - Massachusetts Biomedical Initiatives
TransCode Therapeutics started clinical trials and closed a $30M IPO at MBI, and later had an additional $7M IPO after graduating in 2023.See details»
Nasdaq Determines That TransCode Therapeutics Has Regained …
Jun 10, 2024 We believe our organization is prepared to continue to execute on our ambitious plans to swiftly ... Tania Montgomery-Hammon, VP of Business …See details»
TransCode Therapeutics Inc. - Cruelty Free Investing
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its …See details»
TransCode Therapeutics, Inc. Announces Closing of Registered …
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively …See details»
TransCode Therapeutics Publishes Open Letter Outlining …
Jan 4, 2024 In addition, we have implemented sizable temporary salary reductions for senior management to demonstrate our collective determination to navigate the current economic …See details»
Mission - TRANSCODE THERAPEUTICS, INC.
TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted …See details»
News Releases - TRANSCODE THERAPEUTICS, INC.
Feb 25, 2025 TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA …See details»
TransCode Therapeutics - VentureRadar
Auto Analyst Score: 62 | transcodetherapeutics.com. VentureRadar Popularity. High. VentureRadar Popularity: High. The popularity score combines profile views, clicks and the …See details»
TransCode Therapeutics Publishes Open Letter Outlining …
Jan 4, 2024 TransCode Therapeutics, Inc. Despite Difficult Financial Markets, TransCode Raised New Capital and Initiated Its First Clinical Trial With Its Lead Therapeutic Candidate, A …See details»
Clinical Trials - TRANSCODE THERAPEUTICS, INC.
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been …See details»
TransCode Therapeutics - TransCode Therapeutics Announces …
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer …See details»